You are here: Industry Insights > IONTAS

News List

IONTAS Identifies Novel SARS-CoV-2 Neutralizing Antibodies americanpharmaceuticalreview
March 26, 2021
IONTAS and FairJourney Biologics have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants.
Iontas and Fair Journey Biologics Partner with Quell Therapeutics contractpharma
March 10, 2021
Novel target binders from Iontas/FJB will be used to uncover functional antibodies to advance Quell’s engineered Treg cell therapy pipeline.
FairJourney Biologics, IONTAS enter antibody discovery pact with Pandion Therapeutics expresspharma
November 24, 2020
Diverse panel of novel target binders from FairJourney Biologics and IONTAS will be used to uncover functional antibodies to advance autoimmune and inflammatory disease research.
Iontas Enters Licensing Agreement with Bristol Myers Squibb contractpharma
October 16, 2020
Iontas Limited, a biotechnology company focused on antibody discovery and technology development, has entered into a licensing agreement with Bristol Myers Squibb Company regarding the company’s proprietary mammalian display.
IONTAS and FairJourney Biologics find COVID-19 neutralizing antibodies with picomolar potency expresspharma
September 30, 2020
This viral neutralization efficiency was independently verified by the National Institute for Biological Standards and Control.
FairJourney Biologics Joins Forces with Iontas contractpharma
May 14, 2020
FairJourney Biologics and Iontas, two Clinical Research Organizations (CROs) in antibody discovery services, have combined their operations to create an international platform and provide their industry leading services to global biopharma.
IONTAS, Teva Enter Antibody Optimization Agreement contractpharma
July 30, 2019
Partnership includes options for the screening of biophysical properties suitable for developable antibodies.